公开(公告)号：US20230355678A1

公开(公告)日：2023-11-09

申请号：US18312144

申请日：2023-05-04

Applicant: IMMATICS US, INC.

Inventor： Pooja MEHTA ,  Rene TAVERA ,  Christopher LANIER ,  Mamta KALRA

IPC: A61K35/17 ,  C12N5/0783

CPC classification number: A61K35/17 ,  C12N5/0636 ,  C12N2501/999

Abstract: Methods of manufacturing T cells to improve their efficacy, persistence, memory function, and/or antigen stimulated survival are provided. Methods of manufacturing T cells to improve production of Central Memory T (Tcm) cells are provided. Methods may include culturing or treating T cells with one or more histone deacetylase inhibitor (HDACi) and interleukin-21 (IL-21), with one or more kinase inhibitor, such a tyrosine kinase inhibitor, and/or with one or more AKT inhibitor (AKTi).

公开(公告)号：US20230348561A1

公开(公告)日：2023-11-02

申请号：US18309062

申请日：2023-04-28

Applicant: IMMATICS US, INC.

Inventor： Erik FARRAR ,  Justin GUNESCH ,  Melinda MATA ,  Mohammad HOSSAIN ,  Mamta KALRA ,  Gagan BAJWA

IPC: C07K14/725 ,  C07K14/705 ,  C12N15/63 ,  A61P37/04

CPC classification number: C07K14/7051 ,  C07K14/70517 ,  C12N15/63 ,  A61P37/04

Abstract: The present disclosure relates to T cells capable of co-expressing T cell receptors (“TCR”) together with dominant negative TGFβ Receptor (“dnTGFβR”) polypeptides and/or CD8 polypeptides and the use thereof in adoptive cellular therapy. The present disclosure further provides for dnTGFβR polypeptides, vectors, and associated methods thereof. The present disclosure further provides for modified CD8 polypeptides, vectors, and associated methods of making and using the same.

公开(公告)号：US20220280564A1

公开(公告)日：2022-09-08

申请号：US17281095

申请日：2021-02-23

Applicant: Immatics US, Inc.

Inventor： Melinda MATA ,  Mamta KALRA ,  Ali MOHAMED ,  Steffen WALTER ,  Yannick BULLIARD

IPC: A61K35/17 ,  C07K14/725 ,  C12N5/0783

Abstract: An in vitro method of expanding γδ T cells includes isolating γδ T cells from a blood sample of a human subject, activating the isolated γδ T cells in the presence of an aminobisphosphonate and/or a feeder cell and at least one cytokine, expanding the activated γδ T cells, and optionally restimulating the expanded γδ T cells.

公开(公告)号：US20190216852A1

公开(公告)日：2019-07-18

申请号：US16250679

申请日：2019-01-17

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Agathe BOURGOGNE ,  Ali MOHAMED ,  Steffen WALTER

IPC: A61K35/17 ,  C12N7/00 ,  C12N15/85 ,  A61P35/00

CPC classification number: A61K35/17 ,  A61P35/00 ,  C12N7/00 ,  C12N15/8509

Abstract: The present disclosure relates to T cells transduced with a viral vector at a volumetric concentration for immunotherapy and methods thereof. In another aspect, the present disclosure relates to the assessment of optimal lentiviral vector concentrations for transducing T cells. The present disclosure further provides for T cell populations produced by methods described herein.

公开(公告)号：US20250019655A1

公开(公告)日：2025-01-16

申请号：US18893532

申请日：2024-09-23

Applicant: Immatics US, Inc.

Inventor： Amir ALPERT ,  Mamta KALRA

IPC: C12N5/0783 ,  A61K39/00 ,  A61P35/00 ,  C07K16/28 ,  C12N15/86

Abstract: A method for producing T cells with improved efficacy for adoptive immunotherapy includes obtaining a population of CD8+ T cells from a patient or a donor, determining a % of CD28+ CD8+ T cells in the obtained population, activating the determined population with anti-CD3 antibody and anti-CD28 antibody, provided that the determined population comprises at least 50% of CD28+ CD8+ T cells, or activating the determined population with anti-CD3 antibody in the absence of anti-CD28 antibody, provided that the determined population comprises less than 50% of CD28+ CD8+ T cells, transducing the activated population with a viral vector, and expanding the transduced population, in which the transducing and the expanding are carried out in the presence of at least one cytokine.

公开(公告)号：US20230089392A1

公开(公告)日：2023-03-23

申请号：US17933418

申请日：2022-09-19

Applicant: Immatics US, Inc.

Inventor： Justin GUNESCH ,  Pooja MEHTA ,  Mamta KALRA

IPC: C12N5/0783 ,  C07K14/725 ,  C07K14/705 ,  C07K14/74

Abstract: A method for producing an engineered T cell population includes obtaining a cell population containing a monocyte and a T cell, resting the obtained cell population on a surface, adhering the monocyte to the surface, retaining a non-adherent cell population, activating the non-adherent cell population, introducing a nucleic acid into the activated non-adherent cell population to obtain a transformed T cell, and expanding the transformed T cell to obtain the engineered T cell population.

公开(公告)号：US20220056411A1

公开(公告)日：2022-02-24

申请号：US17409504

申请日：2021-08-23

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Gagan BAJWA ,  Thomas LUCAS ,  Ali MOHAMED ,  Steffen WALTER

IPC: C12N5/0783 ,  C12N15/85 ,  C07K14/725

Abstract: A method of producing an engineered T cell population includes obtaining a cell population comprising a CD8+ T cell, isolating the CD8+ T cell from the obtained cell population, activating the isolated CD8+ T cell, introducing a nucleic acid encoding a T cell receptor (TCR) binding to an antigen in a complex with an MHC molecule into the activated CD8+ T cell, and expanding the introduced CD8+ T cell to obtain the engineered T cell population.

公开(公告)号：US20210030803A1

公开(公告)日：2021-02-04

申请号：US17062331

申请日：2020-10-02

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Zoe Coughlin ,  Amir Alpert ,  Steffen Walter ,  Ali Mohamed ,  Agathe Bourgogne

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C12N15/86 ,  A61P31/00 ,  A61P35/00

Abstract: The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells.

公开(公告)号：US20190247433A1

公开(公告)日：2019-08-15

申请号：US16271393

申请日：2019-02-08

Applicant: Immatics US, Inc.

Inventor： Mamta KALRA ,  Zoe COUGHLIN ,  Amir ALPERT ,  Steffen WALTER ,  Ali MOHAMED ,  Agathe BOURGOGNE

IPC: A61K35/17 ,  C12N5/0783 ,  C07K16/28 ,  C12N15/86 ,  A61P35/00 ,  A61P31/00

CPC classification number: A61K35/17 ,  A61P31/00 ,  A61P35/00 ,  C07K16/2809 ,  C07K16/2818 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N15/86 ,  C12N2501/2302 ,  C12N2501/2307 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2321 ,  C12N2501/51 ,  C12N2501/515 ,  C12N2510/00

Abstract: The disclosure relates to methods of manufacturing T cells for adoptive immunotherapy. The disclosure further provides for methods of genetically transducing T cells, methods of using T cells, and T cell populations thereof. In an aspect, the disclosure provides for methods of thawing frozen peripheral blood mononuclear cells (PBMC), resting the thawed PBMC, activating the T cell in the cultured PBMC with an anti-CD3 antibody and an anti-CD28 antibody immobilized on a solid phase, transducing the activated T cell with a viral vector, expanding the transduced T cell, and obtaining expanded T cells.